Cho, S I; Kim, Y E; Jo, S J
The British journal of dermatology
2020Sep ; 59 ( 18 ) :.
PMID : 32875557
ÀúÀÚ »ó¼¼Á¤º¸
Cho, S I - Department of Dermatology, Seoul National University College of Medicine, Seoul, South Korea.
Kim, Y E - Department of Dermatology, Seoul National University College of Medicine, Seoul,
Jo, S J - Department of Dermatology, Seoul National University College of Medicine, Seoul,
ABSTRACT
BACKGROUND: As the coronavirus disease 2019 (COVID-19) pandemic has spread, information about COVID-19 and skin disease or related biologics is still lacking. OBJECTIVES: To identify the association between COVID-19 and skin diseases or biologics.
METHODS: A nationwide claim dataset relevant to COVID-19 in South Korea was analysed. This dataset included insurance claim data before and during COVID-19 treatment and clinical outcomes. Claim data related to skin diseases and relevant biologics were analysed to determine the association of COVID-19 with skin diseases and relevant biologics.
RESULTS: The dataset contained a total of 234?427 individuals (111?947 male and 122?480 female) who underwent COVID-19 testing. Of them, 7590 (3·2%) were confirmed as having COVID-19, and 227 (3·0%) confirmed patients died. Among various skin diseases and biologics, no significant increase in the presence of specific skin diseases or exposure to biologics was observed in the COVID-19-positive group, even after adjusting for or matching covariates. The presence of skin diseases and exposure to biologics also did not seem to affect clinical outcomes including mortality.
CONCLUSIONS: Underlying skin diseases did not appear to increase susceptibility to COVID-19 or mortality from COVID-19. Considering the risks and benefits, biologics for dermatological conditions might be continuously used during the COVID-19 pandemic. CI - ??2020 British Association of Dermatologists.
na
¸µÅ©